AR041672A1 - Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo - Google Patents
Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararloInfo
- Publication number
- AR041672A1 AR041672A1 ARP030103815A ARP030103815A AR041672A1 AR 041672 A1 AR041672 A1 AR 041672A1 AR P030103815 A ARP030103815 A AR P030103815A AR P030103815 A ARP030103815 A AR P030103815A AR 041672 A1 AR041672 A1 AR 041672A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- heterocyclyl
- independently represent
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto bicíclico de benzamida, o una de sus sales farmacéuticamente aceptables, que tiene la fórmula (1) en la que R1 y R2 representan independientemente halógeno, hidroxi, ciano, nitro, oxo, haloalquilo C1-6, polihaloalquilo C1-6, haloalcoxi C1-6, polihaloalcoxi C1-6, alquilo C1-6, alcoxi C1-6, arilalcoxi C1-6, (alquil C1-6)tio, (alcoxi C1-6)alquilo C1-6; (cicloalquil C3-7)alcoxi C1-6, alcanoilo C1-6, (alcoxi C1-6)carbonilo, arilo, heteroarilo, heterociclilo, arilalquilo C1-6, heteroarilalquilo C1-6, heterociclilaquilo C1-6, (alquil C1-6)sulfonilo, (alquil C1-6)sulfinilo, (alquil C1-6)sulfoniloxi, (alquil C1-6)sulfonilalquilo C1-6, arilsulfonilo, arilsulfoniloxi, arilsulfonilalquilo C1-6, ariloxi, -CO-arilo, -CO-heterociclilo, -CO-heteroarilo, (alquil C1-6)sulfonamidoalquilo C1-6, (alquil C1-6)amidoalquilo C1-6, arilsulfonamido, arilamidosulfonilo, arilsulfonamidoalquilo C1-6, arilcarboxamidoalquilo C1-6, arilalquilo C1-6, arilalcanoilo C1-6, o un grupo NR15R16, -NR15CO-arilo, -NR15CO-heterociclilo, -NR15CO-heteroarilo, -CONR15R16, -NR15COR16, -NR15SO2R16 o -SO2NR15R16, donde R15 y R16 representan independientemente H o alquilo C1-6, donde dichos grupos arilo, heteroarilo y heterociclilo de R1 y R2 pueden estar opcionalmente sustituidos con uno o más (por ejemplo, 1, 2, o 3) sustituyentes que pueden ser iguales o diferentes y que se seleccionan entre halógeno, alquilo C1-6, alcoxi C1-6, oxo, -CF3, -OCF3, -CN, alcanoilo C1-6, (alquil C1-6)sulfonilo, (alquil C1-6)sulfoniloxi, (alquil C1-6)amido o (alquil C1-6)sulfonamido; a y b representan independientemente, 0, 1 o 2, de tal modo que a y b no pueden representar ambos 0; = es un enlace sencillo o doble; R3 representa halógeno, alquilo C1-6, alcoxi C1-6, ciano, amino o trifluorometilo; m y n representan independientemente, 0 1 o 2; p representa un número entero de 0 a 3, de tal modo que cuando p es un número entero mayor que 1, dos grupos R1 pueden en cambio estar unidos para formar un grupo heterociclilo; R4 representa -(CH2)q-NR11R12 o un grupo de la fórmula (2) en la que q es 2, 3, o 4; R11 y R112 representan independientemente alquilo C1-6 o junto con el átomo de N al que están unidos representan un grupo heterocíclico unido a N, opcionalmente sustituido con uno o dos grupos R17; R13 representa H, alquilo C1-6, cicloalquilo C3-8, -(alquil C1-6)-arilo o heterociclilo; R14 y R17 representan independientemente halógeno, alquilo C1-6, haloalquilo C1-6, -OH, di(alquil C1-6)amino o alcoxi C1-6; f y k representan independientemente 0, 1, o 2; g es 0, 1 o 2 y h es 0, 1, 2 o 3, de tal modo que g y h no pueden ser ambos 0; o sus solvatos. Los compuestos bicíclicos de benzamida de la fórmula (1) tienen actividad farmacológica, siendo útiles para preparar composiciones farmacéuticas para el tratamiento de trastornos neurológicos y psiquiátricos. Se propone un procedimiento para la preparación de un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0224557.9A GB0224557D0 (en) | 2002-10-22 | 2002-10-22 | Novel compounds |
GBGB0306328.6A GB0306328D0 (en) | 2002-10-22 | 2003-03-19 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR041672A1 true AR041672A1 (es) | 2005-05-26 |
Family
ID=32178875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030103815A AR041672A1 (es) | 2002-10-22 | 2003-10-20 | Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo |
Country Status (11)
Country | Link |
---|---|
US (2) | US7446103B2 (es) |
EP (1) | EP1554243B1 (es) |
JP (1) | JP2006505623A (es) |
AR (1) | AR041672A1 (es) |
AT (1) | ATE346044T1 (es) |
AU (1) | AU2003278119A1 (es) |
DE (1) | DE60309913T2 (es) |
ES (1) | ES2276125T3 (es) |
GB (2) | GB0224557D0 (es) |
TW (1) | TW200418839A (es) |
WO (1) | WO2004037788A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
WO2003022813A1 (fr) * | 2001-09-07 | 2003-03-20 | Ono Pharmaceutical Co., Ltd. | Derives indole, methode de fabrication et medicaments renfermant lesdits derives en tant que principe actif |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
MXPA05006567A (es) | 2002-12-20 | 2005-08-16 | Glaxo Group Ltd | Derivados de benzazepina para el tratamiento de trastornos neurologicos. |
EP2189448B1 (en) | 2003-06-17 | 2014-01-29 | Arena Pharmaceuticals, Inc. | Processes for the Separation of 3-Benzazepine Racemates |
PL1755593T3 (pl) | 2004-06-02 | 2008-06-30 | Hoffmann La Roche | Pochodne naftalenu przydatne jako ligandy 3-receptora histaminowego |
KR20070083484A (ko) | 2004-07-14 | 2007-08-24 | 피티씨 테라퓨틱스, 인크. | C형 간염 치료 방법 |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
NZ552397A (en) | 2004-07-15 | 2011-04-29 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
EP1632494A1 (en) * | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
KR101281919B1 (ko) | 2004-12-21 | 2013-07-03 | 아레나 파마슈티칼스, 인크. | (r)-8-클로로-1-메틸-2,3,4,5-테트라히드로-1h-3-벤즈아제핀 히드로클로라이드의 결정질 형태 |
PT1833473E (pt) | 2004-12-23 | 2009-12-17 | Arena Pharm Inc | Composições de modulador de receptor 5ht2c e métodos de utilização |
EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
EP1717234A1 (en) * | 2005-04-29 | 2006-11-02 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
WO2007050124A1 (en) * | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
KR101589551B1 (ko) | 2005-07-15 | 2016-02-02 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
AR056690A1 (es) * | 2005-10-14 | 2007-10-17 | Athersys Inc | Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc |
EP2001852A2 (en) | 2006-04-03 | 2008-12-17 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
MX2008013196A (es) * | 2006-04-12 | 2008-10-22 | Hoffmann La Roche | 5-amido-2-carboxiamida-indoles. |
US7928238B2 (en) | 2006-05-11 | 2011-04-19 | Janssen Pharmaceutica Nv | 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors |
JP2009536954A (ja) | 2006-05-11 | 2009-10-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Cetp阻害剤としての3,4−ジヒドロ−2h−ベンゾ[1,4]オキサジンおよびチアジン誘導体 |
CA2670285A1 (en) | 2006-12-05 | 2008-06-12 | Arena Pharmaceuticals, Inc. | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
US7648979B2 (en) * | 2007-02-07 | 2010-01-19 | Hoffmann-La Roche Inc. | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives |
US7960567B2 (en) | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
NZ580802A (en) | 2007-05-10 | 2012-09-28 | Albany Molecular Res Inc | Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
CN101903338A (zh) | 2007-12-19 | 2010-12-01 | 安姆根有限公司 | 用作炎症调节剂的苯基乙酸衍生物 |
JP5491421B2 (ja) | 2008-03-04 | 2014-05-14 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 5−ht2cアゴニストである(r)−8−クロロ−1−メチル−2,3,4,5−テトラヒドロ−1h−3−ベンゾアゼピンに関連する中間体の調製のためのプロセス |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
EP2246331A1 (en) * | 2009-04-24 | 2010-11-03 | Westfälische Wilhelms-Universität Münster | NR2B-selective NMDA-receptor antagonists |
US8802696B2 (en) * | 2009-05-12 | 2014-08-12 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
AU2010247735B2 (en) * | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
CN102648170A (zh) | 2009-06-18 | 2012-08-22 | 艾尼纳制药公司 | 制备5-ht2c受体激动剂的方法 |
EP2459529A1 (en) * | 2009-07-02 | 2012-06-06 | Cephalon, Inc. | Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands |
EP2371808A1 (en) * | 2010-03-08 | 2011-10-05 | Ratiopharm GmbH | Process for preparing dronedarone |
US9045431B2 (en) | 2010-06-02 | 2015-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
ES2704455T3 (es) | 2010-09-01 | 2019-03-18 | Arena Pharm Inc | Formas farmacéuticas de liberación modificada de agonistas de 5-HT2C útiles para la gestión del peso |
WO2012030938A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
CN103189360A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的非吸湿性盐 |
EP2939677A1 (en) | 2010-09-01 | 2015-11-04 | Arena Pharmaceuticals, Inc. | Administration of lorcaserin to indviduals with renal impairment |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
AU2012392187B2 (en) | 2012-10-09 | 2018-07-12 | Arena Pharmaceuticals, Inc. | Method of weight management |
FR3008979B1 (fr) * | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP3071205B1 (en) | 2013-11-18 | 2020-02-05 | Forma Therapeutics, Inc. | Benzopiperazine compositions as bet bromodomain inhibitors |
WO2015074064A2 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
US11046670B2 (en) | 2015-10-19 | 2021-06-29 | Board Of Regents, The University Of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
EP3448520A4 (en) * | 2016-04-29 | 2020-07-29 | Board Of Regents, The University Of Texas System | SIGMA RECEIVER BINDERS |
AU2021325927A1 (en) | 2020-08-14 | 2023-02-23 | Minerva Neurosciences, Inc. | Condensed azacycles as sigma ligand compounds and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU614965B2 (en) * | 1987-06-06 | 1991-09-19 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Thiadiazinones |
EP0639567A1 (en) * | 1992-05-08 | 1995-02-22 | Otsuka Pharmaceutical Factory, Inc. | Indole derivative |
DE69530690T2 (de) | 1994-06-15 | 2004-03-18 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclische derivate verwendbar als vasopressin- oder oxytocin-modulatoren |
JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
WO1998040385A1 (en) * | 1997-03-07 | 1998-09-17 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
PL336628A1 (en) | 1997-05-03 | 2000-07-03 | Smithkline Beecham Plc | Derivatives of tetrahydroisoquinoline as modulators of d3 dopamine receptors |
EP0982300A3 (en) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
ATE259363T1 (de) * | 1999-09-25 | 2004-02-15 | Smithkline Beecham Plc | Piperazinderivate als 5-ht1b antagonisten |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
NZ521192A (en) * | 2000-03-09 | 2005-01-28 | Ono Pharmaceutical Co | Indole derivatives, process for preparation of the same and use thereof |
AU8112101A (en) * | 2000-08-08 | 2002-02-18 | Ortho Mcneil Pharm Inc | Non-imidazole aryloxypiperidines |
AU2001292936A1 (en) * | 2000-09-22 | 2002-04-02 | Ortho-Mcneil Pharmaceutical, Inc. | Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
WO2002076925A2 (en) * | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
EP1395563B1 (en) * | 2001-05-22 | 2006-03-29 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
US7381719B2 (en) | 2002-09-19 | 2008-06-03 | Eli Lilly And Company | Diaryl ethers as opioid receptor antagonist |
GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
GB0224083D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
EP1554260A1 (en) | 2002-10-22 | 2005-07-20 | Glaxo Group Limited | Aryloxyalkylamine derivatives as h3 receptor ligands |
-
2002
- 2002-10-22 GB GBGB0224557.9A patent/GB0224557D0/en not_active Ceased
-
2003
- 2003-03-19 GB GBGB0306328.6A patent/GB0306328D0/en not_active Ceased
- 2003-10-20 AR ARP030103815A patent/AR041672A1/es unknown
- 2003-10-20 AT AT03769430T patent/ATE346044T1/de not_active IP Right Cessation
- 2003-10-20 WO PCT/EP2003/011650 patent/WO2004037788A1/en active IP Right Grant
- 2003-10-20 ES ES03769430T patent/ES2276125T3/es not_active Expired - Lifetime
- 2003-10-20 TW TW092128958A patent/TW200418839A/zh unknown
- 2003-10-20 EP EP03769430A patent/EP1554243B1/en not_active Expired - Lifetime
- 2003-10-20 AU AU2003278119A patent/AU2003278119A1/en not_active Abandoned
- 2003-10-20 US US10/532,373 patent/US7446103B2/en not_active Expired - Fee Related
- 2003-10-20 JP JP2005501524A patent/JP2006505623A/ja active Pending
- 2003-10-20 DE DE60309913T patent/DE60309913T2/de not_active Expired - Fee Related
-
2008
- 2008-09-29 US US12/239,874 patent/US20090042862A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003278119A1 (en) | 2004-05-13 |
DE60309913D1 (de) | 2007-01-04 |
US20070105838A1 (en) | 2007-05-10 |
EP1554243A1 (en) | 2005-07-20 |
GB0224557D0 (en) | 2002-11-27 |
ES2276125T3 (es) | 2007-06-16 |
TW200418839A (en) | 2004-10-01 |
JP2006505623A (ja) | 2006-02-16 |
ATE346044T1 (de) | 2006-12-15 |
GB0306328D0 (en) | 2003-04-23 |
US7446103B2 (en) | 2008-11-04 |
DE60309913T2 (de) | 2007-06-28 |
US20090042862A1 (en) | 2009-02-12 |
EP1554243B1 (en) | 2006-11-22 |
WO2004037788A1 (en) | 2004-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR041672A1 (es) | Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo | |
AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
AR042542A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y proceso para su preparacion | |
AR038966A1 (es) | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 | |
AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
AR033306A1 (es) | Compuestos | |
WO2002089800A3 (en) | N-aroyl cyclic amine derivatives as orexin receptor antagonists | |
AR051294A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
AR038420A1 (es) | Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
AR051090A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
AR057981A1 (es) | Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion | |
AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
BR1100514A (pt) | Processo para a preparação de compostos derivados do ácido benzimidazolino - 2 - oxo - 1 - carboxìlico; produto / composto / composição | |
AR051091A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
AR035325A1 (es) | Derivados de adamantano, un proceso para su preparacion, composicion farmaceutica, un proceso para la preparacion de dicha composicion, y el uso de dichos derivados para la fabricacion de un medicamento | |
CA2570807A1 (en) | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
AR065927A1 (es) | Derivados de 5,6-dihidro-1h-piridin-2-ona | |
AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
AR050698A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto | |
AR038249A1 (es) | Compuestos derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos derivados en la preparacion de un medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |